Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H27N3O7S |
Molecular Weight | 501.552 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(O)=O
InChI
InChIKey=JAYVKNDQKXUNOJ-UHFFFAOYSA-N
InChI=1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)
PG-116800 is a member of the hydroxyproline-based hydroxamic acid class of matrix metalloproteinase (MMP) inhibitors. PG-116800 did not modify matrix structure in osteoarthritic patients. Also, it had unexpected side effects on muscle and skeleton; it limited joint mobility, and caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s contracture and persistent tendon thickness or nodules. PG-116800 failed to reduce left ventricular remodeling or improve clinical outcomes after myocardial infarction.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. | 2006 Jul 4 |
|
The quest for the Holy Grail: a disease-modifying osteoarthritis drug. | 2007 |
|
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. | 2007 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17958901
25 mg, 50 mg, 100 mg, or 200 mg taken twice daily for 12 months
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C512048
Created by
admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
|
PRIMARY | |||
|
F94T42GL80
Created by
admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
|
PRIMARY | |||
|
DB05495
Created by
admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
|
PRIMARY | |||
|
9848869
Created by
admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
|
PRIMARY | |||
|
291533-11-4
Created by
admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
|
PRIMARY | |||
|
DTXSID10951756
Created by
admin on Sat Dec 16 02:31:10 GMT 2023 , Edited by admin on Sat Dec 16 02:31:10 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD